The Journal of Infectious Diseases · 2000 · 57 citations · 40 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyImmunology Of Infectious DiseasesImmunopharmacologyCell-mediated ImmunityImmunodeficiency DisordersImmunomodulatory DrugsImmunosuppressionT Cell ActivationT Cell BiologyAntigen-induced Lymphocyte ProliferationAntigen-specific T Cell ResponsesCd4 Positive T CellsCd8 Positive T Cell ResponsesCd8 Positive T CellsLymphocyte Proliferation InhibitionT-cell Immune ResponsesT-cell Mediated Responses
Thalidomide, which inhibits monocyte tumor necrosis factor (TNF)-alpha production and costimulates T cells, was tested for immune modulation in patients with human immunodeficiency virus (HIV) infection and tuberculosis (TB) in a placebo-controlled study. Thalidomide therapy resulted in increased levels of plasma interleukin (IL)-2 receptor, soluble CD8, interferon-gamma, and IL-12, indicating immune stimulation. TNF-alpha levels were not reduced. Thalidomide treatment increased CD4+ and CD8+ T cell counts and lymphocyte proliferation to purified protein derivative. Immune stimulation was not associated with an increase in plasma HIV levels. In vivo, a thalidomide dose-dependent costimulatory effect on T cell proliferation and HIV replication was observed after stimulation with antigens or anti-CD3, respectively. Thalidomide-induced increased viral replication in CD4+ T cells was abrogated by adding back autologous CD8+ T cells. Thus, in the presence of thalidomide, antigen-specific immune responses in vitro and in patients with HIV/TB were enhanced.
40
L Osborn, S L Kunkel, Gary J. Nabel · Proceedings of the National Academy of Sciences · 1989 · 1.6K citations · Full text
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
Bruce Beutler, David A. Greenwald, J D Hulmes et al. · Nature · 1985 · 1.1K citations